Crystallographic study of a novel subnanomolar inhibitor provides insight on the binding interactions of alkenyldiarylmethanes with human immunodeficiency virus-1 reverse transcriptase.
Cullen, M.D., Ho, W.C., Bauman, J.D., Das, K., Arnold, E., Hartman, T.L., Watson, K.M., Buckheit, R.W., Pannecouque, C., De Clercq, E., Cushman, M.(2009) J Med Chem 52: 6467-6473
- PubMed: 19775161
- DOI: https://doi.org/10.1021/jm901167t
- Primary Citation of Related Structures:
3IRX, 3IS9 - PubMed Abstract:
Two crystal structures have been solved for separate complexes of alkenyldiarylmethane (ADAM) nonnucleoside reverse transcriptase inhibitors (NNRTI) 3 and 4 with HIV-1 reverse transcriptase (RT). The structures reveal inhibitor binding is exclusively hydrophobic in nature and the shape of the inhibitor-bound NNRTI binding pocket is unique among other reported inhibitor-RT crystal structures. Primarily, ADAMs 3 and 4 protrude from a large gap in the back side of the binding pocket, placing portions of the inhibitors unusually close to the polymerase active site and allowing 3 to form a weak hydrogen bond with Lys223. The lack of additional stabilizing interactions, beyond the observed hydrophobic surface contacts, between 4 and RT is quite perplexing given the extreme potency of the compound (IC(50)
Organizational Affiliation:
Department of Medicinal Chemistry and Molecular Pharmacology, School of Pharmacy and Pharmaceutical Sciences, and Purdue University Center for Cancer Research, Purdue University, West Lafayette, Indiana 47907, USA.